Anti-cytokeratin CAM5.2 Recognized CK8 Mainly, but not CK18: Comment on “Early Assessment of Axillary Response with 18F-FDG PET/CT During Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: Implications for Surgical Management of the Axilla. Annals of Surgical Oncology doi: 10.1245/s10434-013-2902-0 (2013)” Wan-Ru ChaoChih-Ping Han Translational Research and Biomarkers 08 November 2013 Pages: 699 - 699
Reply to “Anti-cytokeratin CAM5.2 Recognized CK8 Mainly, but not CK18: Comment on ‘Early Assessment of Axillary Response with 18F-FDG PET/CT During Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: Implications for Surgical Management of the Axilla. Ann Surg Oncol. 2013;20(7):2227–35’” Bas B. KoolenJelle Wesseling Breast Oncology 20 September 2013 Pages: 700 - 700